Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban
Francisco Marı́n(Instituto Murciano de Investigación Biosanitaria), Manuel Anguita Sánchez(Mayo Clinic in Florida), Jaime Masjuán(Universidad de Alcalá), Fernando Arribas(Hospital Universitario 12 De Octubre), José Manuel Vázquez‐Rodríguez(Complexo Hospitalario Universitario A Coruña), Marcelo Sanmartı́n(Universidad de Alcalá), Alejandro Pérez Cabeza(Centro de Investigación en Red en Enfermedades Cardiovasculares), Román Freixa‐Pamias(Hospital de Sant Joan Despí Moisès Broggi), Gonzalo Barón‐Esquivias(San Raffaele University of Rome), Vanessa Roldán(Hospital Universitario Virgen de la Arrixaca), Esther Recalde Del Vigo(Hospital de Basurto), Iñaki Lekuona(Hospital de Galdakao), Vivencio Barrios(Apple (Israel))
Cited by 2
Related Papers
Guidelines on the management of valvular heart disease (version 2012)
|European Heart Journal|2012|3.6k
Guidelines on the management of valvular heart disease (version 2012)
|European Journal of Cardio-Thoracic Surgery|2012|2k
2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed Under the Auspices of the ESC Committee for Practice Guidelines
|European Journal of Heart Failure|2016|1.8k
Rosuvastatin in Older Patients with Systolic Heart Failure
|New England Journal of Medicine|2007|1.5k
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
|New England Journal of Medicine|2019|823